Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (July 2023)
20 slides from Curis's investor presentation, Jul 6, 2023
Slide 1: Corporate Presentation
Corporate Presentation NASDAQ: CRIS © 2023 Curis, Inc. EXHIBIT 99.2
Slide 2: Cautionary Note Regarding Forward Looking Statements and Disclaimers
Cautionary Note Regarding Forward Looking Statements and Disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “beli
Slide 3: Investment Thesis
Investment Thesis Emavusertib, a triple target inhibitor, has the potential to be the cornerstone agent in hematologic malignancies Cash runway into 2025 – $71.8M as of March 31, 2023 Lead Programs TakeAim Leukemia – IRAK4 and FLT3 are the most prevalent drivers of disease in AML/MDS1,2 TakeAim Lymp
Slide 4: Recent Developments
Recent Developments Current status o Expanding monotherapy in genetically-defined R/R AML population (potential for fast path to NDA) Next steps o Clarify monotherapy registrational study design in leukemia with FDA o Expand into front-line combination therapy in leukemia (potential for broad commer
Slide 5: Emavusertib: Mechanism and Design
Emavusertib: Mechanism and Design
Slide 6: Mechanism of Action
Mechanism of Action IRAK4 is a novel and important target in AML/MDS 1) Guillamot et al. Nat Cell Biol 2019; 2) Smith et al. Nat Cell Biol 2019; 3) American Cancer Society, Cancer Facts & Figures 2020; 4) Leukemia & Lymphoma Society, Facts and Statistics Overview Myddosome IRAK1 IRAK4-S MYD88 Myddos
Slide 7: Unique Molecular Fingerprint
Unique Molecular Fingerprint Targeted design is specifically engineered to be the best-in-class Emavusertib Kinase Interaction Map % Inhibition at 0.1 nM Illustration reproduced courtesy of Cell Signaling Technology Target Kd nM IRAK1 12,000 IRAK2 >20,000 IRAK3 8,500 IRAK4 23 DYRK1A 25 FLT3 wt FLT3
Slide 8: Emavusertib in Leukemia (AML/MDS)
Emavusertib in Leukemia (AML/MDS)
Slide 9: All Patients in AML/MDS: Single Agent Anti-Cancer Activity
-100% -80% -60% -40% -20% 0% 20% 40% 60% 80% 100% -100% -80% -60% -40% -20% 0% 20% 40% 60% 80% 100% All Patients in AML/MDS Emavusertib shows clear single agent anti-cancer activity slide 9 Note: 84 total patients enrolled as of Feb 9, 2023 with data cut-off as of Mar 17, 2023 * 3 AML patients had b
Slide 10: Genetically-Defined Target Population
Genetically-Defined Target Population Significant blast count reductions observed with monotherapy in targeted patient populations slide 10 CR CR MLFS -100% -80% -60% -40% -20% 0% CR CRh -100% -80% -60% -40% -20% 0% ** 7 patients AML with FLT3 Mutation* 8 patients AML with Spliceosome Mutation* ** *
Slide 11: Genetically-Defined Target Population: Deeper Responses with ≤2 Prior Lines
CR CR MLFS -100% -80% -60% -40% -20% 0% CR CRh -100% -80% -60% -40% -20% 0% Genetically-Defined Target Population Additional signal observed: patients with ≤ 2 prior lines are achieving deeper responses slide 11 ** 7 patients AML with FLT3 Mutation* 8 patients AML with Spliceosome Mutation* ** ** 30
Slide 12: Preclinical Data
0% p<0.05 p<0.05 50% 100% -50% Preclinical Data Rationale for monotherapy and combination with azacitidine/venetoclax 1) Choudhary et al. AACR 2017; 2) Melgar, Sci Transl Med. 2019; 3) Curis AML MDS poster, EHA 2021 Control R e la ti ve C el l G ro w th Aza Aza + emavusertib Aza/Ven slide 12 Clinica
Slide 13: Clinical Strategy in Leukemia
Clinical Strategy in Leukemia TakeAim Leukemia Strategy for Monotherapy and Combination Potential for front-line position Combination Enroll 20 Patients (1L) all comers o 1st line AML combination with aza/ven o 1st line MDS combination TBD For each indication, collect clinical data in ~20 patients t
Slide 14: Emavusertib in Lymphoma (NHL/CLL)
Emavusertib in Lymphoma (NHL/CLL)
Slide 15: Emavusertib in Lymphoma
Emavusertib in Lymphoma Combination therapy provides complimentary inhibition of two pathways that drive NF-κB NFκB Biology: Two Pathways Drive NHL/CLL BCR and TLR Pathways independently drive NF-κB overactivity (and NF-κB drives NHL/CLL) Clinical Strategy: Block both pathways with Combination Thera
Slide 16: Initial Clinical Data in Lymphoma
Initial Clinical Data in Lymphoma Majority of patients achieved decreases in tumor burden, including complete responses -100% -80% -60% -40% -20% 0% 20% 40% 60% 80% 100% 0 50 100 150 200 250 300 % C h an ge in T u m o r B u rd en f ro m B as el in e Study Day slide 16 BTK-naïve BTK-experienced NHL/C
Slide 17: Clinical Strategy in Lymphoma
Clinical Strategy in Lymphoma The ideal candidate to combine with BTKi to maximize downregulation of NF-κB • Patients are currently treated with BTKi because it downregulates NF-κB • Two pathways drive NF-κB: 1) BCR Pathway: addressed by blocking BTK 2) TLR Pathway: addressed by blocking IRAK4 • Ini
Slide 18: Potential Cornerstone Treatment for Hematologic Malignancies
Leukemia Emavusertib synergizes with existing treatments5 as IRAK4-L is expressed in nearly all AML/MDS patients Monotherapy targets the two largest genetically-defined patient populations in AML/MDSa,6-8 Lymphoma Potential Cornerstone Treatment for Hematologic Malignancies Emavusertib inhibits both
Slide 19: Investment Thesis
Investment Thesis Emavusertib, a triple target inhibitor, has the potential to be the cornerstone agent in hematologic malignancies Cash runway into 2025 – $71.8M as of March 31, 2023 Lead Programs TakeAim Leukemia – IRAK4 and FLT3 are the most prevalent drivers of disease in AML/MDS1,2 TakeAim Lymp
Slide 20: End of Presentation
End of Corporate Presentation NASDAQ: CRIS